Senate Finance Committee Ranking Member Ron Wyden, D-Ore., along with several other Democratic senators, yesterday introduced bills aimed at increasing transparency for prescription drug prices and reducing costs for Medicare Part D enrollees. The Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act (S. 474) would require the Health and Human Services Secretary to notify drug makers when the price of their drug increases beyond certain benchmarks, and require drug makers to submit a timely justification for price increases to HHS, among other provisions. The Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act (S. 476) would require pharmacy benefit managers to publicly disclose the aggregate amount of rebates they receive from pharmaceutical companies and the proportion of those rebates that go to Medicare beneficiaries, and base cost-sharing for Part D enrollees on the negotiated price of the drug, among other provisions. The Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act (S. 475) would eliminate all cost-sharing for Medicare Part D beneficiaries once they reach the catastrophic phase.

Related News Articles

Headline
The Department of Health and Human Services’ Office of Inspector General yesterday proposed excluding from safe harbor protection under the Anti-Kickback…
Perspective
Last week, I shared a few areas where we can advance health in America this year, even in a divided Congress.
Headline
The AHA today voiced support for a Centers for Medicare…
Headline
The Centers for Medicare & Medicaid Services today issued a
Headline
The House of Representatives yesterday passed two bills that would prohibit health plans from restricting a pharmacist’s ability to inform enrollees when a…
Headline
The Senate last night voted 98-2 to approve the Patient Right to Know Drug Prices Act (S. 2554), a bill that would prohibit private health plans from…